Search for: "Sanofi S A"
Results 61 - 80
of 933
Sort by Relevance
|
Sort by Date
2 Oct 2023, 9:32 pm
By Kevin E. [read post]
29 Sep 2023, 2:52 am
The US Supreme Court decision in Amgen v Sanofi concluded that making all of the antibodies falling under the epitope claim of Amgen's patent would be undue burden for the skilled person. [read post]
28 Sep 2023, 6:22 am
Sanofi</em> appeared first on Gibbons Law Alert. [read post]
28 Sep 2023, 6:22 am
Sanofi</em> appeared first on Gibbons Law Alert. [read post]
28 Sep 2023, 6:22 am
Sanofi</em> appeared first on Gibbons Law Alert. [read post]
20 Sep 2023, 9:39 am
Sanofi, 598 U.S. 594 (2023). [read post]
10 Sep 2023, 9:15 am
Sanofi, 143 S. [read post]
10 Sep 2023, 9:15 am
Sanofi, 143 S. [read post]
26 Aug 2023, 9:16 am
‘But the Court would have none of it, finding that the order was issued based on MyStromer’s request, which did not cover Austria. [read post]
2 Aug 2023, 11:28 am
Sanofi. [read post]
2 Aug 2023, 11:05 am
Sanofi argued on appeal that the Board erroneously agreed with Mylan’s argument that de Gennes constituted analogous art because Mylan incorrectly compared the de Gennes reference to another prior art reference, and not the ’614 patent. [read post]
31 Jul 2023, 1:18 am
The Board of Appeal dismissed the Patentee's nuclear bomb argument, on the grounds that a skilled person would not consider these embodiments technically reasonable. [read post]
28 Jul 2023, 8:26 am
However, it follows a similar action filed in May by Lake County, Illinois in which the County accuses Eli Lilly, Novo Nordisk, Sanofi, Express Scripts, and OptumRx are accused of violating the state's Consumer Fraud Act and the RICO Act. [read post]
20 Jul 2023, 3:44 am
The UK therefore appears at risk of continued divergence from the EPO on the correct legal test for the standard of evidence in sufficiency and inventive step.Sandoz v BMS: Facts of the caseThe case in Sandoz v BMS related to BMS's European (UK) patent EP 1427415. [read post]
20 Jul 2023, 1:42 am
Part 2 will consider the Court of Appeal's interpretation of G 2/21. [read post]
15 Jul 2023, 6:00 am
Sanofi NG 598/2 23 5/18/23 21-869 Andy Warhol Foundation for Visual Arts, Inc. v. [read post]
15 Jul 2023, 6:00 am
Sanofi NG 598/2 23 5/18/23 21-869 Andy Warhol Foundation for Visual Arts, Inc. v. [read post]
13 Jul 2023, 5:01 am
Sanofi. [read post]
9 Jul 2023, 8:40 pm
Sanofi regarding the sufficiency of disclosure needed to satisfy the statutory enablement requirement under 35 US.C. [read post]
3 Jul 2023, 3:00 am
Sanofi to require that the full scope of the claims must be enabled. [read post]
